GleamWall
中文EN

HSTC HST Global, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 797564 · Fiscal year ends 12/31

Financial factors as of 2024-09-30 (2024Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY30.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-29.7%
ROA-15.8%
ROIC (approx.)-23.1%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets3.3%
Debt / equity0.00x
Current ratio0.25x
Interest coverage-28.94x

Cash quality & payout

Operating cash flow / net income0.38x
Accruals ratio-9.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20232023-12-31FY20222022-12-31
Income statement
Revenue$0$0
SG&A expense$20,907$21,035
Operating income-$140,907-$141,035
Interest expense$5,303$4,039
Income tax$0$0
Net income-$146,210-$145,074
EPS (basic)-0.03-0.03
EPS (diluted)——
Balance sheet
Cash & equivalents$1,526$190
Current assets$1,526$190
Intangibles$0—
Total assets$1,526$190
Current liabilities$593,593$446,047
Total liabilities$593,593$446,047
Shareholders' equity-$592,067-$445,857
Shares outstanding5.25M5.25M
Cash flow statement
Operating cash flow-$20,906-$21,035
Investing cash flow$0$0
Financing cash flow$22,242$21,000

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.